{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Bipolar+Disorder+With+Psychotic+Features",
    "query": {
      "condition": "Severe Bipolar Disorder With Psychotic Features"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Bipolar+Disorder+With+Psychotic+Features&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T10:18:51.427Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01259427",
      "title": "Reducing Internalized Stigma in People With Serious Mental Illness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder",
        "Major Depression With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Ending Self Stigma (ESS)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health and Wellness Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 252,
      "start_date": "2011-10",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2016-03-08",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Perry Point",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01259427"
    },
    {
      "nct_id": "NCT01570972",
      "title": "Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder With Psychotic Features",
        "Major Depression With Psychotic Features",
        "Psychotic Disorder Not Otherwise Specified (NOS)"
      ],
      "interventions": [
        {
          "name": "Group Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Multifamily Group Psychoeducation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 103,
      "start_date": "2010-02",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570972"
    },
    {
      "nct_id": "NCT01878513",
      "title": "Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Psychotic Disorder Not Otherwise Specified",
        "Severe Bipolar Disorder With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 88,
      "start_date": "2009-09-23",
      "completion_date": "2018-07-31",
      "has_results": false,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01878513"
    },
    {
      "nct_id": "NCT01731119",
      "title": "Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Schizophreniform Disorder",
        "Psychosis NOS",
        "Autistic Disorder",
        "Asperger Syndrome",
        "Child Development Disorders, Pervasive",
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Mood Disorder NOS",
        "Severe Major Depression With Psychotic Features",
        "Single Episode Major Depression Without Psychotic Symptoms",
        "Severe Mood Disorder With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Latuda©",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "6 Years to 19 Years"
      },
      "enrollment_count": 9,
      "start_date": "2012-12",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01731119"
    },
    {
      "nct_id": "NCT05877716",
      "title": "EPI-MINN: Targeting Cognition and Motivation - National",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psychosis",
        "Psychosis Nos/Other",
        "Schizophrenia",
        "Schizo Affective Disorder",
        "Schizoaffective Disorder",
        "Prodromal Schizophrenia",
        "Schizophrenia Spectrum and Other Psychotic Disorders",
        "Schizophreniform Disorders",
        "Major Depression With Psychotic Features",
        "Unspecified Psychosis",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Cognitive and Social Cognitive Training",
          "type": "DEVICE"
        },
        {
          "name": "Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Early Psychosis Coordinated Specialty Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 200,
      "start_date": "2023-05-30",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-21",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877716"
    },
    {
      "nct_id": "NCT00421954",
      "title": "Open-label Ziprasidone Study for Psychosis Treatment in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophreniform Disorder",
        "Schizoaffective Disorder",
        "Psychosis",
        "Depressive Disorder, Major",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2006-05",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421954"
    },
    {
      "nct_id": "NCT00531518",
      "title": "Early Detection and Intervention for the Prevention of Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Bipolar Disorder",
        "Depression",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine",
          "type": "DRUG"
        },
        {
          "name": "Psychoeducational multifamily group treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Supported employment and education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "MaineHealth",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Years to 25 Years"
      },
      "enrollment_count": 292,
      "start_date": "2007-10",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-08-15",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 6,
      "location_summary": "Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Maine"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00531518"
    },
    {
      "nct_id": "NCT04004416",
      "title": "Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Bipolar Disorder",
        "Healthy",
        "Psychosis",
        "Schizophreniform Disorders",
        "Schizo Affective Disorder",
        "Major Depression With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Placebo and fMRI",
          "type": "OTHER"
        },
        {
          "name": "Lorazepam and fMRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 143,
      "start_date": "2020-01-16",
      "completion_date": "2025-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04004416"
    },
    {
      "nct_id": "NCT01597141",
      "title": "Psychosis: Early Detection, Intervention and Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prodromal Schizophrenia",
        "Psychotic Disorders",
        "Severe Bipolar Disorder With Psychotic Features",
        "Severe Major Depression With Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Family-aided Assertive Community Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced standard treatment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "MaineHealth",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 100,
      "start_date": "2003-05",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "Portland, Maine",
      "locations": [
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597141"
    },
    {
      "nct_id": "NCT00179062",
      "title": "Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Depressive Disorder, Major",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "olanzapine versus risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 300,
      "start_date": "2000-02",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2008-08-26",
      "last_synced_at": "2026-06-10T10:18:51.427Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179062"
    }
  ]
}